Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America and the Caribbean

QUIÑONES LA; LAVANDEROS MA; CAYÚN JP; GARCÍA-MARTIN E; AGÚNDEZ JA; CÁCERES DD; ROCO AM; MORALES JE; HERRERA L; ENCINA G; ISAZA C; REDAL MA; LARÓVERE LAURA ELENA; SORIA NW; ESLAVA-SCHMALBACH J; CASTAÑEDA-HERNÁNDEZ G; LÓPEZ-CORTÉS A; MAGNO LA; LÓPEZ M; CHIURILLO M; RODEIRO I; CASTRO DE GUERRA D; TERÁN E; ESTEVEZ-CARRIZO, F; LARES-ASSEF I

CURRENT DRUG METABOLISM

BENTHAM SCIENCE PUBL LTD

Lugar: Oak Park; Año: 2014 vol. 15 p. 202 - 202

1389-2002

p>Pharmacogenetics and Pharmacogenomics areas are currently emerging fields focused to manage pharmacotherapy that may prevent undertreatment while avoiding associated drug toxicity in patients. Large international differences in the awareness and in the use of pharmacogenomic testing are presumed, but not well assessed to date. In the present study we review the awareness of Latin American scientific community about pharmacogenomic testing and the perceived barriers for their clinical application. In order to that, we have compiled information from 9 countries of the region using a structured survey which is compared with surveys previously performed in USA and Spain. The most relevant group of barriers was related to the need for clear guidelines for the use of pharmacogenomics in clinical practice, followed by insufficient awareness about pharmacogenomics among clinicians and the absence of regulatory in